A trial of G-CSF combined with DVCLP regimen as the remission induction therapy for adults with acute lymphoblastic Leukemia

HE Jing,CHEN Yan

DOI: https://doi.org/10.3969/j.issn.1001-9057.2006.07.011

2006-01-01

Abstract:Objective To evaluate the efficacy of G-CSF combined with DVCLP regimen as the remission induction therapy for adult ALL.Methods Newly diagnosed patients (n=40) received DVCLP regimen as the remission induction therapy.In the study group(n=20),patients received G-CSF beginning 3 days before the chemotherapy until day 7.In the control group (n=20),G-CSF was administered only when ANC was <1.5x10~9/L.Results The median time of neutropenia(ANC<1.5×10~9/L) was 16+7 days for the study group and 21+5days for the control group(P<0.05).The rate of complete remission,relapse rate,the median overall survival and estimated one year survival in the study group are 85%,22%,11 months and 45%;and those numbers in the control group are 75%,55%,6 months,and 19%(P>0.05).Conclusions The use of G-CSF in the early phase of the remission induction therapy for adult ALL can significantly shorten the time of neutropenia.But its positive roles of increasing complete remission rate,decreasing relapse rate and improving the long survival did not reach the statistical difference.